SCHEMBL38653272

SCHEMBL38653272

CN(C)c1cc(F)c2c(c1)CN(C(=O)OC(C)(C)C)C2

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ESR2 Q92731 1/20 0.41
▸ NR1H2 P55055 2/20 0.41
▸ MAPK1 P28482 1/20 0.41
▸ DDB1 Q16531 2/20 0.40
▸ CRBN Q96SW2 2/20 0.40
▸ HDAC1 Q13547 1/20 0.40
▸ NAMPT P43490 2/20 0.36
▸ DPP4 P27487 1/20 0.36
▸ KDM4E B2RXH2 1/20 0.36
▸ MAPT P10636 1/20 0.36
▸ THRB P10828 1/20 0.36
▸ BACE1 P56817 1/20 0.35
▸ MMP13 P45452 1/20 0.35
▸ TGM2 P21980 2/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ GPR119 Q8TDV5 2/20 0.35
▸ F13A1 P00488 1/20 0.35
▸ TGM1 P22735 1/20 0.35
▸ USP30 Q70CQ3 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL38653301 0.89 ESR2 (0.50) ESR2NR1H2MAPK1DDB1CRBN
SCHEMBL19357854 0.85 HDAC1 (0.42) ESR2NR1H2MAPK1DDB1CRBN
SCHEMBL31158935 0.83 HDAC1 (0.44) ESR2NR1H2MAPK1DDB1CRBN
SCHEMBL30666316 0.83 ESR2 (0.53) ESR2NR1H2MAPK1DDB1CRBN
SCHEMBL30666328 0.82 USP30 (0.45) ESR2NR1H2MAPK1DDB1CRBN
SCHEMBL30666315 0.81 ESR2 (0.42) ESR2NR1H2MAPK1DDB1CRBN
SCHEMBL29124891 0.81 ESR2 (0.42) ESR2NR1H2MAPK1DDB1CRBN
SCHEMBL23253904 0.79 ESR2 (0.54) ESR2NR1H2MAPK1DDB1CRBN
SCHEMBL38653719 0.79 ESR2 (0.54) ESR2NR1H2MAPK1DDB1CRBN
SCHEMBL31158757 0.79 GPR119 (0.45) ESR2NR1H2MAPK1DDB1CRBN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4741375-A1 SULFONYLUREA DERIVATIVES AND THEIR USE FOR THE TREATMENT OF CANCER Qubit Pharmaceuticals (FR) 2026-05-13 — — EP disclosed
Send feedback